Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Model-based vs Empirical Piperacillin/Tazobactam Dosing in Preterm Neonates with Late-Onset Sepsis
NCT05981079Phase 4Unknown
- Sponsor
- Shandong University
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of piperacillin + tazobactam in sepsis, sponsored by Shandong University. Status: unknown.
02
Drugs
piperacillin + tazobactam
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05981079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981079.